Literature DB >> 21539880

A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Iana H Haralambieva1, Inna G Ovsyannikova, Megan O'Byrne, V Shane Pankratz, Robert M Jacobson, Gregory A Poland.   

Abstract

The measurement of measles-specific neutralizing antibodies, directed against the surface measles virus hemagglutinin and fusion proteins, is considered the gold standard in measles serology. We assessed functional measles-specific neutralizing antibody levels in a racially diverse cohort of 763 young healthy adolescents after receipt of two doses of measles-mumps-rubella vaccine, by the use of an automated plaque reduction microneutralization (PRMN) assay, and evaluated their relevance to protective antibody levels, as well as their associations with demographic and clinical variables. We also concurrently assessed measles-specific IFNγ Elispot responses and their relation to the observed antibody concentrations. The geometric mean titer for our cohort was 832mIU/mL (95% CIs: 776; 891). Sixty-eight subjects (8.9%) had antibody concentrations of less than the protective threshold of 210mIU/mL (corresponding to PRMN titer of 120; suggesting protection against symptomatic disease), and 177 subjects (23.2%) demonstrated persisting antibody concentrations above 1841mIU/mL (corresponding to PRMN titer of 1052; suggesting total protection against viral infection), 7.4 years after vaccination, in the absence of wild-type virus boosting. The mean measles-specific IFNγ Elispot response for our cohort was 46 (95% CIs: 43; 49) IFNγ-positive spots per 200,000 cells with no relation of cellular immunity measures to the observed antibody concentrations. No significant associations between antibody titers and demographic and clinical variables, including gender and race, were observed in our study. In conclusion, in a large observational study of measles immunity, we used an automated high-throughput measles virus-specific neutralization assay to measure humoral immunity, and concurrently determined measles-specific cellular immunity to aid the assessment of potential susceptibility to measles in vaccinated populations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21539880      PMCID: PMC3117252          DOI: 10.1016/j.vaccine.2011.04.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

1.  Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.

Authors:  J Mossong; C J O'Callaghan; S Ratnam
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

2.  Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines.

Authors:  Hershel Jick; Katrina Wilcox Hagberg
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

3.  Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

Authors:  R G Pebody; N J Gay; L M Hesketh; A Vyse; P Morgan-Capner; D W Brown; P Litton; E Miller
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Gender differences in the reactogenicity of measles-mumps-rubella vaccine.

Authors:  T Shohat; M S Green; O Nakar; A Ballin; P Duvdevani; A Cohen; M Shohat
Journal:  Isr Med Assoc J       Date:  2000-03       Impact factor: 0.892

5.  Association of parental vaccination reports with measles, mumps, and rubella protective antibody levels: comparison of Somali immigrant, Hispanic migrant, and US children in Rochester, Minn.

Authors:  Jennifer L St Sauver; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; Erin M Green; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2002-03       Impact factor: 7.616

6.  Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.

Authors:  S Atabani; G Landucci; M W Steward; H Whittle; J G Tilles; D N Forthal
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

7.  Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity.

Authors:  J Mossong; D J Nokes; W J Edmunds; M J Cox; S Ratnam; C P Muller
Journal:  Am J Epidemiol       Date:  1999-12-01       Impact factor: 4.897

8.  Racial differences in HLA class II associations with hepatitis C virus outcomes.

Authors:  C L Thio; D L Thomas; J J Goedert; D Vlahov; K E Nelson; M W Hilgartner; S J O'Brien; P Karacki; D Marti; J Astemborski; M Carrington
Journal:  J Infect Dis       Date:  2001-05-30       Impact factor: 5.226

9.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.

Authors:  H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin
Journal:  J Infect Dis       Date:  2001-08-22       Impact factor: 5.226

10.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization.

Authors:  G A Poland; I G Ovsyannikova; R M Jacobson; R A Vierkant; S J Jacobsen; V S Pankratz; D J Schaid
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

View more
  37 in total

1.  Independence of measles-specific humoral and cellular immune responses to vaccination.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2012-03-03       Impact factor: 2.850

2.  Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.

Authors:  Benjamin J Umlauf; Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

3.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Authors:  T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

5.  Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Megan M O'Byrne; Robert M Jacobson; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-20       Impact factor: 3.641

6.  Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-27       Impact factor: 3.641

Review 7.  Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.

Authors:  Christopher C Stobart; Martin L Moore
Journal:  Expert Rev Vaccines       Date:  2015-10-05       Impact factor: 5.217

8.  Associations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Gregory A Poland
Journal:  Hum Immunol       Date:  2013-02-13       Impact factor: 2.850

Review 9.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

10.  Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.

Authors:  Amy Parker Fiebelkorn; Laura A Coleman; Edward A Belongia; Sandra K Freeman; Daphne York; Daoling Bi; Ashwin Kulkarni; Susette Audet; Sara Mercader; Marcia McGrew; Carole J Hickman; William J Bellini; Rupak Shivakoti; Diane E Griffin; Judith Beeler
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.